Sean K. Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sean K. Lau has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Lawrence M. Weiss
13 shared publicationsPeiguo G. Chu
7 shared publicationsLawrence M Weiss
Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA
4 shared publicationsYibin Zhang
3 shared publicationsYuan-Yuan Chen
Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA
2 shared publicationsAdam N Mamelak
Division of Surgery, City of Hope National Medical Center, Duarte, CA, USA
1 shared publication
Latest Publications
- 31 December 2011
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 15 (6) , 485-489
Oncocytoma of the kidney with prominent intracytoplasmic lumina
- 31 December 2011
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 15 (6) , 485-489
Oncocytoma of the kidney with prominent intracytoplasmic lumina
- 1 June 2011
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 15 (3) , 185-189
Mixed cortical adenoma and composite pheochromocytoma-ganglioneuroma: an unusual corticomedullary tumor of the adrenal gland
- 1 June 2011
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 15 (3) , 185-189
Mixed cortical adenoma and composite pheochromocytoma-ganglioneuroma: an unusual corticomedullary tumor of the adrenal gland
- 1 October 2010
- Published by Elsevier in Human Pathology
- Vol. 41 (10) , 1500-1504
Myopericytoma of the kidney
- 1 October 2010
- Published by Elsevier in Human Pathology
- Vol. 41 (10) , 1500-1504
Myopericytoma of the kidney
- 4 June 2010
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 122 (3) , 637-645
Papillary carcinoma of the breast: an overview
Papillary carcinoma of the breast represents ~0.5% of all newly diagnosed cases of breast cancer. The prevalence of both invasive and in situ papillary carcinoma seems to be greater in older postmenopausal women and, in relative terms, in males. Histologic features of the tumor include cellular proliferations surrounding fibrovascular cores, with or without invasion. In this review, characteristics of both in situ and invasive disease are outlined. Immunohistochemical analyses of papillary carcinoma suggest the utility of markers such as smooth muscle myosin heavy chain, calponin, p63, and high molecular weight keratins, which can characterize the myoepithelial cell layer. With respect to radiographic evaluation of papillary carcinoma, ultrasonography is the most extensively studied imaging modality, though magnetic resonance mammography has potential utility. Available data suggest improved outcome for papillary carcinoma as compared to invasive ductal carcinoma. Treatment-related information for patients with papillary carcinoma is limited, and patterns noted in available series suggest a variable approach to this disease. The scarcity of information underscores the need for further treatment- and outcome-related studies in papillary carcinoma of the breast.
- 4 June 2010
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 122 (3) , 637-645
Papillary carcinoma of the breast: an overview
Papillary carcinoma of the breast represents ~0.5% of all newly diagnosed cases of breast cancer. The prevalence of both invasive and in situ papillary carcinoma seems to be greater in older postmenopausal women and, in relative terms, in males. Histologic features of the tumor include cellular proliferations surrounding fibrovascular cores, with or without invasion. In this review, characteristics of both in situ and invasive disease are outlined. Immunohistochemical analyses of papillary carcinoma suggest the utility of markers such as smooth muscle myosin heavy chain, calponin, p63, and high molecular weight keratins, which can characterize the myoepithelial cell layer. With respect to radiographic evaluation of papillary carcinoma, ultrasonography is the most extensively studied imaging modality, though magnetic resonance mammography has potential utility. Available data suggest improved outcome for papillary carcinoma as compared to invasive ductal carcinoma. Treatment-related information for patients with papillary carcinoma is limited, and patterns noted in available series suggest a variable approach to this disease. The scarcity of information underscores the need for further treatment- and outcome-related studies in papillary carcinoma of the breast.
- 1 May 2010
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 18 (3) , 273-277
Immunohistochemical Evaluation of CON6D/B5
Immunohistochemical evaluation of CD30 expression is commonly performed in the assessment of hematopoietic disorders and germ cell tumors. A new monoclonal antibody, CON6D/B5, directed against the CD30 antigen has become commercially available for use in formalin-fixed paraffin-embedded tissue samples. The performance characteristics of CON6D/B5 were tested and compared with the well-characterized monoclonal CD30 antibody Ber-H2. Among the various neoplasms analyzed, there was complete concordance between the results of CON6D/B5 and Ber-H2 staining. Similar to Ber-H2, CON6D/B5 immunoreactivity was observed in all cases of classical Hodgkin lymphoma, anaplastic large cell lymphoma, and embryonal carcinoma, with no staining detectable in any of the other various tumors evaluated, including several neoplasms earlier reported as showing CD30 positivity by other investigators. The labeling intensity was much stronger with CON6D/B5 compared with Ber-H2, although no significant differences were observed with regard to the numbers of positively labeled cells in individual cases. The monoclonal antibody CON6D/B5 offers a suitable alternative to Ber-H2 for the immunohistochemical detection of CD30 expression.
- 1 May 2010
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 18 (3) , 273-277
Immunohistochemical Evaluation of CON6D/B5
Immunohistochemical evaluation of CD30 expression is commonly performed in the assessment of hematopoietic disorders and germ cell tumors. A new monoclonal antibody, CON6D/B5, directed against the CD30 antigen has become commercially available for use in formalin-fixed paraffin-embedded tissue samples. The performance characteristics of CON6D/B5 were tested and compared with the well-characterized monoclonal CD30 antibody Ber-H2. Among the various neoplasms analyzed, there was complete concordance between the results of CON6D/B5 and Ber-H2 staining. Similar to Ber-H2, CON6D/B5 immunoreactivity was observed in all cases of classical Hodgkin lymphoma, anaplastic large cell lymphoma, and embryonal carcinoma, with no staining detectable in any of the other various tumors evaluated, including several neoplasms earlier reported as showing CD30 positivity by other investigators. The labeling intensity was much stronger with CON6D/B5 compared with Ber-H2, although no significant differences were observed with regard to the numbers of positively labeled cells in individual cases. The monoclonal antibody CON6D/B5 offers a suitable alternative to Ber-H2 for the immunohistochemical detection of CD30 expression.
- 1 July 2009
- Published by Elsevier in Pathology - Research and Practice
- Vol. 205 (7) , 508-512
Nested variant of urothelial carcinoma of the renal pelvis
- 1 July 2009
- Published by Elsevier in Pathology - Research and Practice
- Vol. 205 (7) , 508-512
Nested variant of urothelial carcinoma of the renal pelvis
- 1 June 2009
- Published by Elsevier in Human Pathology
- Vol. 40 (6) , 757-768
The Weiss system for evaluating adrenocortical neoplasms: 25 years later
- 1 June 2009
- Published by Elsevier in Human Pathology
- Vol. 40 (6) , 757-768
The Weiss system for evaluating adrenocortical neoplasms: 25 years later
- 13 February 2009
- Published by Wiley in Diagnostic Cytopathology
- Vol. 37 (5) , 359-364
Cytomorphologic features of the plasmacytoid variant of urothelial carcinoma: A case report
The plasmacytoid variant of urothelial carcinoma is an uncommon form of urothelial carcinoma with a distinctive histologic appearance. Descriptions of the cytologic features of this particular type of urothelial carcinoma in urinary specimens are limited. The present report details the urinary cytomorphologic findings of a plasmacytoid urothelial carcinoma occurring in the urinary bladder of a 66‐year‐old male. Bladder washings showed the presence of scattered dyscohesive cells with a plasmacytoid appearance characterized by abundant amounts of cytoplasm, eccentrically located nuclei, and inconspicuous nucleoli. The diagnosis of plasmacytoid urothelial carcinoma was confirmed upon histologic examination of a concurrently performed transurethral resection specimen, with immunohistochemical studies supporting this interpretation. Although rare, the plasmacytoid variant of urothelial carcinoma should be a diagnostic consideration when atypical cells with plasmacytoid features are encountered in a urinary specimen. Diagn. Cytopathol. 2009.
- 13 February 2009
- Published by Wiley in Diagnostic Cytopathology
- Vol. 37 (5) , 359-364
Cytomorphologic features of the plasmacytoid variant of urothelial carcinoma: A case report
The plasmacytoid variant of urothelial carcinoma is an uncommon form of urothelial carcinoma with a distinctive histologic appearance. Descriptions of the cytologic features of this particular type of urothelial carcinoma in urinary specimens are limited. The present report details the urinary cytomorphologic findings of a plasmacytoid urothelial carcinoma occurring in the urinary bladder of a 66‐year‐old male. Bladder washings showed the presence of scattered dyscohesive cells with a plasmacytoid appearance characterized by abundant amounts of cytoplasm, eccentrically located nuclei, and inconspicuous nucleoli. The diagnosis of plasmacytoid urothelial carcinoma was confirmed upon histologic examination of a concurrently performed transurethral resection specimen, with immunohistochemical studies supporting this interpretation. Although rare, the plasmacytoid variant of urothelial carcinoma should be a diagnostic consideration when atypical cells with plasmacytoid features are encountered in a urinary specimen. Diagn. Cytopathol. 2009.
- 6 January 2009
- Published by Springer Nature in Virchows Archiv
- Vol. 454 (2) , 189-194
Myxoid solitary fibrous tumor: a clinicopathologic study of three cases
While focal myxoid areas are occasionally observed in solitary fibrous tumors, neoplasms of this type exhibiting extensive myxoid change are considered exceedingly uncommon. Due to their rarity, the biologic behavior of myxoid solitary fibrous tumor has not been determined. Three cases of myxoid solitary fibrous tumor are described in order to better characterize the clinical and pathologic features of this uncommon variant of solitary fibrous tumor. The tumors occurred in one man and two women, with ages of 37, 47, and 58 years, respectively. Sites of involvement included the retroperitoneum, pelvis, and soft tissue of the neck. Histologically, all cases were characterized predominantly by the presence of myxoid stroma comprising 70% to 100% of the tumor. The tumor cells were predominantly spindled in all cases, and arranged randomly, in loose fascicles, or in anastomosing strands imparting a microcystic/reticular appearance. The lesional cells had a bland cytologic appearance and low mitotic count. All tumors lacked necrosis and areas of increased cellularity. By immunohistochemistry, all cases were positive for CD34, CD99, and bcl-2, and negative for keratin, epithelial membrane antigen, desmin, actin, smooth muscle actin, and S-100 protein. To date, all cases have followed a benign course without evidence of recurrence or metastasis with a follow-up duration ranging from 50 to 87 months. The data suggest that myxoid solitary fibrous tumors are associated with an indolent clinical course and favorable prognosis.
- 6 January 2009
- Published by Springer Nature in Virchows Archiv
- Vol. 454 (2) , 189-194
Myxoid solitary fibrous tumor: a clinicopathologic study of three cases
While focal myxoid areas are occasionally observed in solitary fibrous tumors, neoplasms of this type exhibiting extensive myxoid change are considered exceedingly uncommon. Due to their rarity, the biologic behavior of myxoid solitary fibrous tumor has not been determined. Three cases of myxoid solitary fibrous tumor are described in order to better characterize the clinical and pathologic features of this uncommon variant of solitary fibrous tumor. The tumors occurred in one man and two women, with ages of 37, 47, and 58 years, respectively. Sites of involvement included the retroperitoneum, pelvis, and soft tissue of the neck. Histologically, all cases were characterized predominantly by the presence of myxoid stroma comprising 70% to 100% of the tumor. The tumor cells were predominantly spindled in all cases, and arranged randomly, in loose fascicles, or in anastomosing strands imparting a microcystic/reticular appearance. The lesional cells had a bland cytologic appearance and low mitotic count. All tumors lacked necrosis and areas of increased cellularity. By immunohistochemistry, all cases were positive for CD34, CD99, and bcl-2, and negative for keratin, epithelial membrane antigen, desmin, actin, smooth muscle actin, and S-100 protein. To date, all cases have followed a benign course without evidence of recurrence or metastasis with a follow-up duration ranging from 50 to 87 months. The data suggest that myxoid solitary fibrous tumors are associated with an indolent clinical course and favorable prognosis.
- 1 April 2008
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 32 (4) , 615-619
Immunohistochemical Expression of Langerin in Langerhans Cell Histiocytosis and Non-Langerhans Cell Histiocytic Disorders
Langerin is a type II transmembrane C-type lectin associated with the formation of Birbeck granules in Langerhans cells. Langerin is a highly selective marker for Langerhans cells and the lesional cells of Langerhans cell histiocytosis. Although Langerin protein expression in Langerhans cell histiocytosis has been previously documented, the specificity of Langerin expression as determined by immunohistochemistry in the context of other histiocytic disorders has not been well established. In the present study, Langerin immunoreactivity was examined in a series of histiocytic disorders of monocyte/macrophage and dendritic cell derivation to assess the specificity and utility of Langerin as a diagnostic marker for Langerhans cell histiocytosis. Immunohistochemical expression of CD1a was also evaluated for comparison. Seventeen cases of Langerhans cell histiocytosis and 64 cases of non-Langerhans cell histiocytic disorders were examined. Langerin and CD1a were uniformly expressed in all cases of Langerhans cell histiocytosis, with the exception of one case that was positive for Langerin and negative for CD1a. Among the non-Langerhans cell histiocytic disorders evaluated, focal Langerin immunoreactivity was observed only in 2 of 10 cases of histiocytic sarcoma. All non-Langerhans cell histiocytic disorders showed no expression of CD1a. Langerin expression seems to be a highly sensitive and relatively specific marker of Langerhans cell histiocytosis. Immunohistochemical evaluation of Langerin expression may have utility in substantiating a diagnosis of Langerhans cell histiocytosis and separating this disorder from other non-Langerhans cell histiocytic proliferations.
- 1 April 2008
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 32 (4) , 615-619
Immunohistochemical Expression of Langerin in Langerhans Cell Histiocytosis and Non-Langerhans Cell Histiocytic Disorders
Langerin is a type II transmembrane C-type lectin associated with the formation of Birbeck granules in Langerhans cells. Langerin is a highly selective marker for Langerhans cells and the lesional cells of Langerhans cell histiocytosis. Although Langerin protein expression in Langerhans cell histiocytosis has been previously documented, the specificity of Langerin expression as determined by immunohistochemistry in the context of other histiocytic disorders has not been well established. In the present study, Langerin immunoreactivity was examined in a series of histiocytic disorders of monocyte/macrophage and dendritic cell derivation to assess the specificity and utility of Langerin as a diagnostic marker for Langerhans cell histiocytosis. Immunohistochemical expression of CD1a was also evaluated for comparison. Seventeen cases of Langerhans cell histiocytosis and 64 cases of non-Langerhans cell histiocytic disorders were examined. Langerin and CD1a were uniformly expressed in all cases of Langerhans cell histiocytosis, with the exception of one case that was positive for Langerin and negative for CD1a. Among the non-Langerhans cell histiocytic disorders evaluated, focal Langerin immunoreactivity was observed only in 2 of 10 cases of histiocytic sarcoma. All non-Langerhans cell histiocytic disorders showed no expression of CD1a. Langerin expression seems to be a highly sensitive and relatively specific marker of Langerhans cell histiocytosis. Immunohistochemical evaluation of Langerin expression may have utility in substantiating a diagnosis of Langerhans cell histiocytosis and separating this disorder from other non-Langerhans cell histiocytic proliferations.